1. Home
  2. TRDA vs LCNB Comparison

TRDA vs LCNB Comparison

Compare TRDA & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.46

Market Cap

268.6M

Sector

Health Care

ML Signal

HOLD

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$19.37

Market Cap

223.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
LCNB
Founded
2016
1877
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
268.6M
223.1M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
TRDA
LCNB
Price
$6.46
$19.37
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$21.00
N/A
AVG Volume (30 Days)
345.9K
33.1K
Earning Date
05-08-2026
04-22-2026
Dividend Yield
N/A
5.43%
EPS Growth
N/A
68.04
EPS
N/A
0.31
Revenue
$25,421,000.00
$6,445,000.00
Revenue This Year
$39.97
$8.50
Revenue Next Year
$50.80
$3.66
P/E Ratio
N/A
$63.90
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$14.11
52 Week High
$16.45
$20.62

Technical Indicators

Market Signals
Indicator
TRDA
LCNB
Relative Strength Index (RSI) 40.49 63.56
Support Level $5.75 $16.16
Resistance Level $7.02 N/A
Average True Range (ATR) 0.46 0.71
MACD -0.06 0.17
Stochastic Oscillator 13.87 63.31

Price Performance

Historical Comparison
TRDA
LCNB

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

Share on Social Networks: